ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

Study enrollment began in August 2015, and results are expected in the third quarter of 2021 (depending on the actual event rate).